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An overwhelming push in HIV research has been made towards developing a ‘functional 
cure’, with the overarching goal being to eliminate or control the virus without the need for 
continued antiretroviral drug therapy. Successful immunotherapeutic strategies are now 
mainstream as anti-cancer treatments have encouraged exploration into the development of novel 
immunotherapies to treat HIV. Importantly in public health, new insights into the complexities of 
how the immune system functions in both health and disease continue to provide room for 
developing novel and improved therapies. Because dendritic cells (DC) play a central role in the 
crosstalk between the innate and adaptive branches of the immune response, they have been 
widely considered for their therapeutic potential for both HIV and cancer. Yet in order to 
capitalize on their strengths in this regard, there is still a need to better understand the basics of 
how they function and communicate with other immune cells.  In this study, we explore the basic 
role DC-derived extracellular vesicles play in the immune crosstalk between DC and T cells, 
characterizing mechanisms of their release, their transfer to T cells, their phenotype, and their 
functional impact on cellular immune responses to viral antigens. It is our position that 
information gained from this work may contribute to the development of novel and improved 
therapies to treat chronic diseases such as HIV-1 infection. 
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Chronic diseases such as cancer and HIV have long been a burden to society, and are 
observed frequently along with other infectious diseases [1]. Despite advancements in 
therapeutics, the number of people infected with HIV across the globe is approximately 37.9 
million according to WHO reports, and approximately 17 million new cancer diagnoses occur 
resulting in approximately 9.6 million deaths each year worldwide.  The use of various 
chemotherapeutic approaches and combination anti-retroviral therapy (ART) have played a 
major role in controlling these diseases [2], but they do not come without major side effects. 
Moreover, their increased application is also fueled with raised concerns for the potential 
development of drug resistance [3, 4]. On a positive note, there have been great strides made in 
terms of not just prevention, but also therapeutics to lessen burden, limit new cases, and to even 
cure some of those affected by these chronic diseases.  Importantly, advances in technologies and 
our understanding of immunology in general has led to the development of novel and promising 
immunotherapeutic strategies.   
 In cancer, the treatments have moved from standard highly toxic and non-specific 
treatments such as chemo and radiation therapy, to more advanced immunotherapeutic 
approaches such as developments of tumor vaccines, monoclonal antibodies, immune checkpoint 
inhibitors, and T cell therapies including the use of genetically engineered chimeric antigen 
receptor T cells (CAR-T cells) [5, 6]. Likewise, the push in current HIV therapy is to move 
towards finding either a ‘cure’ or a ‘functional cure’, where the goal is to have people currently 
living with HIV to acquire the means to clear the infection completely or to control the virus 
themselves immunologically without the need for continued ART. One concept highly touted is 
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the “Kick and Kill” approach, whereby latency reversal agents (LRAs) are used to kick-start 
transcription of integrated inactive/silent HIV DNA for subsequent recognition and elimination 
by immune effector cells such as HIV specific cytotoxic T cell lymphocytes (CTL) [7]. 
Currently, various latency reversal targets including HDAC inhibitors, TLR agonists, PKC 
activators, and cytokines have been tested for therapeutic applications, but have yet to show 
substantial clinical improvements. Moreover, some of the most effective LRA’s have 
demonstrated toxicities and/or negative impacts on CTL function [8]. Hence there is still a need 
to establish novel therapeutics with improved outcomes for treating chronic HIV infection.  
 A recent report by Kristoff et al brought forward a clever and promising strategy to utilize 
dendritic cells (DC) as a cellular immunotherapy tool drive both HIV latency reversal as well as 
the activation of CTL effectors capable of effectively targeting the infected CD4+ T cells 
exposed [9].    
1.1 Dendritic Cells 
1.1.1 Origin 
The term ‘dendritic cells’ was coined by Dr.Ralph Steinmann and Zanvil Cohn in 1973, 
after the earlier discovery by pathologist Elie Metchnikoff of cells that had the ability to 
phagocytose invading pathogens. They were recognized for their integral part in both innate and 
adaptive immune responses and thus playing an vital role as a natural link between the innate and 
adaptive immune system [10, 11]. Due to their potent antigen presenting capabilities, DC and 
their various subsets are collectively referred to as ‘professional’ antigen-presenting cells (APC), 
3 
being the primary cell type with the ability to process and cross-present exogenous antigen in the 
context of both MHC-class I and II molecules to prime naïve T cells. Cross presentation is the 
ability of an APC to process and present an exogenous antigen via MHC class I to naïve CD8 T-
cells mediated via either a cytosolic or vacuolar pathway [12]. Because of this, they have been 
widely utilized as an immunotherapeutic tool to treat chronic diseases including cancer and HIV 
[13, 14]. 
1.1.2 Distribution and Immunological function 
Immature dendritic cells (iDC) reside at sites of entry for common infections like gut, 
skin, mucosal surfaces. iDC have high phagocytic activity but low MHC class I and II presenting 
capabilities. They efficiently process engulfed microbes and become activated by various 
microbial derivatives recognized by their highly specialized pattern recognition receptors (PRRs) 
that identify conserved regions of pathogen associated molecular patterns (PAMPs). During this 
stage of invasion, in addition to iDC being activated by pathways downstream of PRRs, they also 
respond to endogenous environmental signals, such as cytokines and inflammatory products 
from other immune cells responding to the pathogen induced assault. A result of these combined 
signaling factors ultimately leads to activation and maturation of DC, resulting in decreased 
phagocytic activity and enhanced phenotypic characteristics such as surface expression of MHC 
and co-stimulatory molecules such as CD80 and CD86 (Figure 1) and the lymph node homing 
chemokine receptor CCR7 [15, 16]. Mature DC then migrate to the draining lymph nodes to 
activate residing naïve and central memory CD8+ and CD4+ T cells by presenting antigen in the 
context of MHC-class I and MHC-class II molecules respectively (signal 1) along with the co-
stimulatory molecules (signal 2) [17-21]. 
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Figure 1. Role of mature DC in activating T-cells  
(Horig, H., et al., Expert reviews in molecular medicine, 2000). 
(A) In the presence of co-stimulatory molecules CD80 and CD86, DC activate T-cells via interactions with CD28 on 
T-cells thus activating them in the LN (B) Lack of co-stimulatory molecules, despite presence of signal1 via MHC-
TCR interaction leads to anergy of CD4+ T cells [22]. 
1.1.3 Antigen presentation and priming of T cells 
DC process the antigen and present them on MHC (I/II) depending on source of antigen. 
Exogenous peptides are typically presented via MHC class II, which aids in the activation of 
CD4+ T cells. Endogenous peptides are typically presented via MHC class I, which helps in 
triggering CD8+ T cells [23]. This MHC-associated presentation of peptide antigen to activate 
antigen specific T cell receptors is termed as ‘signal 1’. Simultaneously, the co-stimulatory 
molecules provided, which is referred to as ‘signal 2’, determines the magnitude and duration of 
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the T-cell response directed towards the peptide antigen presented by the DC. In the absence of 
co-stimulatory molecules, the T-cells enter a state of anergy or tolerance [24]. A few examples of 
this are CD80 (B7.1), CD86 (B7.2) and 4IBBL, which interact with various receptors on T cells. 
Further, an additional set of factors provided by DC, collectively known as ‘signal 3’, which 
include cytokines such as IL-12p70, direct the functional differentiation of T cells to greatly 
influence the nature and overall character of immune response mediated by the T cells to match 
the nature of the pathogen and affected tissues (Figure 2). Examples of this includes the 
differentiation of naïve CD4+ T cells into T helper (Th)1, Th2 and Th17 cells [25]. A few factors 
that determine the effector response of T cells include combinations of the type of pathogen, 
tissue derived factors, and type of TLRs activated in the DC [26]. T-cells are then directed by 
DC to carry out their effector activity in specific tissue sites of infection. This directed homing 
process is sometimes referred to as DC-mediated ‘signal 4’.  At this time, it is not entirely clear 
what combination of factors contribute to signal 4 or what exactly determines the outcome of this 
process. However, signals provided to T-cells by tissue specific DC greatly influence this 
process. For example, DC from Peyer’s patch have been shown to upregulate 𝛼4𝛽7 integrins on 
CD8+ T cells which aid in homing towards the gut [27]. In a similar manner, DC activated in the 
skin increased P & E-Selectin on CD8+ T cells [28]. 
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Figure 2. Signal 3 provided by DC skews the immune system 
(Marek Jutel et al. Current allergy and asthma report, 2011)  
Signal 3 is important to determine the polarization status of T-cells depending on the type of pathogen encountered 
and cytokines produced in accordance  to direct the type of T-cell response [29]. 
 
1.1.4 Role of DC in mediating CD4+ T cell ‘Help’, and the role of CD40L 
DC also play a special role in driving the cytotoxic effector functions of CD8+ T cells.  
Importantly, the capacity of DC to induce effector CTL differentiation and long-term survival is 
greatly impacted by the nature of their interaction with CD4+ T helper cell.  During their antigen 
specific interaction with DC, CD4+ T cells provide important ‘helper’ signals to the DC, which 
hyper-activates mature DC, causing further upregulation in their expression of co-stimulatory 
molecules and release of cytokines that influences CTL generation. An important factor  
mediating this enhanced CTL inducing capacity in DC  is the CD4 ‘T-helper’ signal CD40L [30-
32]. CD40L is a transmembrane glycoprotein that is part of the TNF-superfamily. CD40L 
expression is induced on the Th cells when they are provided the DC-mediated signals 1 and 2.  
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CD40L interacts with CD40 expressed on the antigen presenting DC, mediating DC upregulation 
of surface expression of MHC, costimulatory molecules CD80/CD86, and the production of  
IL12p70 [33]. This aids in the licensing of DC to promote CTL response, subsequently 
increasing its proliferative capabilities. Lack of CD40-CD40L signal, reduces the property of DC 
to induce secondary expansion of CTLs, thus indicating a role of CD40L in the help for long-
term CTL survival [30, 31, 34].  
Importantly, DC can have very different responses to CD40L depending on the 
environmental factors they encounter during maturation. DC matured in the presence of PGE-2 
and LPS, while highly stimulatory have been shown to have diminished IL-12p70 producing 
capabilities, but demonstrate enhanced IL-12p40 production [35]. IL-12-p70 is an important 
regulator of Th-1 mediated responses [36], while IL-12p40 acts as an inhibitor for the 
biologically active IL-12p70 [37]. The capacity for mature DC to produce IL-12p70 in response 
to CD40L is influenced heavily by the presence of the cytokine IFN-, which can occur either 
during the environmental instruction or programming phases of DC maturation followed by 
subsequent interaction with CD40L expression CD4+ Th cells, or when simultaneously present 
during the moment when mature DC are actively interacting with the CD4+ Th cells in the 
lymph node.  The source of IFN- can come from effector cell types including CD8+ T cells, NK 
cells, or Th1 cells.  Importantly, CD40L is most uniquely associated with CD4+ T cells, 
expressed on the surface following their antigen specific activation [38]. This CD40L- and IFN- 
mediated IL-12p70 together helps to drive primary type-1 responses in responding naïve T-cells 
[39]. On the other hand, the presence PGE-2, a mediator of chronic inflammation,  facilitates DC 
driven type-2 response [37]. As eluded to earlier, the combination of environmental signals 
received by the DC during maturation greatly determines the nature of their responsiveness to 
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subsequent CD40L signaling they may receive during their antigen specific interaction with T 
cells in the lymph node, and they may be pre-programmed or polarized to bias the ensuing 
adaptive T cell responses towards a particular immune character (i.e. Th1, Th2, Th9, Th17, 
Th22, T reg).  
More recent studies from our group have shown other interesting effects of CD40L 
stimulation of mature DC that also impacts the outcome of the adaptive immune response.  For 
example, PD-L1 is expressed moderately on mature DC, but is highly upregulated following 
their activation with CD40L [40].  PD-L1 is well known as an important immune checkpoint 
ligand that binds to PD-1 on activated PD-1 expressing CTLs, which results in the suppression of 
their effector response by inhibiting the action of PI3K [40, 41]. Interestingly, the function of 
PD-L1 expressed on DC appears to be context dependent, as it supports naïve T cell 
differentiation into their effector cell phenotype while it inhibits late stage effector T cell 
function [40].  Another study from our group defined a novel immunologic process referred to as 
DC ‘reticulation’, which highlights intriguing differences in the nature of the responsiveness to 
CD40L expressing Th cells by differentially matured or polarized DC [42].  Type-1 polarized 
dendritic cells (DC1) in particular respond to CD40L to dramatically undergo this reticulation 
process, in which they form extensive networks of tunneling nanotubes (TNTs). These TNTs 
were shown to facilitate intercellular transfer of content, including antigen, between DC [42]. 
While highly speculative, this may help to explain how migratory DC deliver peripheral antigen 
to resident DC in the lymph node [43, 44]. Although it is widely accepted that CD40L plays a 
critical role in DC mediated CTL responses, there are aspects of this interaction that are not 
clearly elucidated and remain unexplored.  
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1.2 Role of DC in Immunotherapy 
DC have been used as a therapeutic option owing to their ability to elicit strong primary 
and memory T cell responses. In the setting of cancer, there have been many clinical trials 
utilizing DC as a cellular vaccine tool [45]. The most common DC type used in early clinical 
trials have been generated from monocyte precursors that are cultured in the presence of IL-4 
and GM-CSF and differentiated into iDC ex-vivo, and then exposed to a cocktail maturation 
factors including TNFa, IL-1b, IL-6 and PGE2 to generate mature DC [46, 47]. This method 
yields a DC type that is highly stimulatory, however it was found to be defective in its capacity 
to produce IL-12p70 in response to CD40L, and has been shown to drive Th2 [47] and T-reg 
responses preferentially. Other protocols for DC generation have since been created to improve 
on this point. One clinically applicable DC generation protocol was created to generate a 
specialized DC1 cellular vaccine tool, referred to as alpha-DC1 (DC1) [48]. This platform was 
developed for the specific purpose of generating monocyte derived mature DC that had a 
superior capacity to produce IL-12p70 and to induce strong CTL responses against cancer 
antigens, and utilized a combination of type-1 and type-2 interferons and the TLR3 agonist poly-
IC to mature the DC. When loaded with tumor antigen, DC1 were found to drive increased 
IFN- producing CTLs compared to the standard PGE2 matured DC [48]. The increase in  IFN- 
is attributed to elevated T-bet expression in the CTLs. During clinical trials, alpha DC1 were 
shown to re-polarize Th2 skewed CD4+ T cells toward acquiring a Th1 functional status, while 
simultaneously increasing CTL responses toward particular epitopes in melanoma patients and 
breast cancer patients [49, 50]. The same pattern was shown in Chronic lymphocytic leukemia 
(CLL) patient derived DC1 showing the CTL induction against CLL [51]. One impressive 
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clinical trial for glioblastoma showed clinical responses of a delay of recurrence of tumor and 
enhanced longevity with use of DC1 [52].  The positive responses were associated with the IL-
12p70 producing capacity of the DC1 generated from study participants, and these patients 
recorded upregulation of mRNA for chemokine CXCL10 and IFN-, of which CXCL10 was 
found to home T-cell response towards the brain [52]. Another study showed that delivery of 
murine DC (DC1-like) engineered to overexpress T-bet promoted superior cytotoxic responses 
by CTLs, while simultaneously decreasing the level of T-regulatory cells present [53].   
In the setting of HIV, there have been a number of clinical trials using autologous DC as 
a therapeutic vaccine, including the use of antigen in the form of HIV-derived peptides, 
inactivated HIV, and autologous apoptotic HIV-infected CD4+ T cells [54-56]. Unfortunately, 
the results of most of these studies have been underwhelming, with limited enhancement of HIV-
specific CTL responses, sometimes accompanied with enhancement of T reg activity [57].  But, 
there have been a few trials in particular that did yield somewhat impressive results though, 
where treatment with autologous DC loaded with inactivated HIV was found to significantly 
decrease residual viremia associated with induced CTL responses [58] and increase in the 
percentage of activated CD4+ T cells [59]. Albeit these studies used MDDCs generated via 
conventional cocktails involving PGE-2, which produce low levels of IL12-p70 production.  
More recently, a DC-based clinical trial using DC generated in the presence of IFN- showed 
promise, where the authors reported inverse correlation between breadth of IL-13 producing 
CD4 T-cells and HIV levels and active cytokine production and increased % of polyfunctional 
CD8+ T cells restricted to specific HIV epitopes post cART interruption 16 weeks after 
vaccination [60]. 
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A major hurdle in therapy is the latency of HIV in CD4+ T cells. Interestingly, 
administration of DC pulsed with autologous HIV, meant to enhance CTL responses, instead 
showed an increase in viremia during ART [61, 62], indicating the ability of DC to ‘Kick’ HIV 
from its CD4 reservoir. Related to this notion, recently published data from our lab has displayed 
the ability of DC1 (referred to in the paper as monocyte derived DC1 or MDC1) presenting 
CMV or HIV antigen could specifically reverse latency, and that this effect involved the 
CD40L/CD40 signaling pathway [9]. This study suggested that a substantial portion of the HIV 
reservoir may be contained within the CMV antigen specific T cell fraction of the CD4+ T cells. 
This study also suggested that utilization of heterologous CMV antigen may help to promote 
CD4+ T cell ‘help’ to the DC to license CTL inducing capacity while providing specific antigen 
to drive the LRA effect.  Therefore, it is proposed that if programmed properly, DC can be used 
as an all-in-one cellular therapeutic “Kick and Kill” tool [9] (Fig 3). Again, the bidirectional talk 
between DC and CD4+ T helper cells and CD40L signaling was found to play a major role in 
this LR activity. However, the downstream mechanisms involved in the CD40L-mediated LRA 
effect have yet to be elucidated. 
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Figure 3. Alpha DC1 driven “Kick and Kill” of HIV 
(Jan Kristoff et al. viruses,  2019)  
Alpha DC1 induces the antigen-specific CD4+ and CD8+ T cells responses by targeting CMV-specific CD4+ T 
cells and resulting in latency reversal of HIV and simultaneously signaling via CD40-CD40L interaction to release 
IL12-p70 to drive the action of cytotoxic CTLs to kill these infected cells [63]. 
 
 
Allan et al. have displayed the ability of migratory DC to transfer antigen to the lymph node 
and this is needed by the resident DC to induce cellular immunity by interacting with CD8+ T 
cells, while migratory DC interact with CD4+ T cells [43]. Later, it was shown by these CD8- 
migratory DC were more in number in the LN and better at inducing Ifn-gamma production from 
CD8+ T cells, than CD8+ resident DC [44]. These suggest an interaction between the various 
DC subtypes and T-cells, while the nature of the interaction remains to be explored. Recently, 
Zaccard et al identified a novel process deemed DC reticulation in DC treated with CD4 T helper 
signal CD40L, which interacts with CD40 on the surface of DC. It was shown that these 
reticulation aka tunneling nanotubes (TNTs) were shown to enhance transfer of bacteria and 
other cytoplasmic content between DC [42]. Related findings from the Storkus lab at the 
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University of Pittsburgh has shown in-vivo using murine models, the transfer of T-bet from T-bet 
overexpressing DC to CD8+ T cells, and their preliminary data suggest a potential role for 
exosome delivery of this factor [53].  
These data, along with previously mentioned interaction between various DC subtypes, 
gives rise to unknown features of intercellular communication. A driving question is if there is a 
dependence on CD40L for this communication, and does the polarization status of the DC 
influence this process, as it does for the TNT-based intercellular transfer [42]. Other unpublished 
data from our lab indicates the ability for DC to facilitate HIV to trans-infection is enhanced 
DC1 than standard DC types matured in the absence of type-1 polarizing factors, in a manner 
dependent on subsequent CD40L signaling. The downstream mechanisms involved in this 
CD40L-mediated trans-infection process, whether mediated through TNTs, or extracellular 
vesicles, or some other processes, have yet to be determined.  
1.3 Extracellular Vesicles 
1.3.1 Origin 
Extracellular vesicles (EVs) were initially discovered in 1946. They were originally 
postulated to be waste particulate secreted by cells. Later, it was observed in multiple instances 
that this serves as a means of communication between cells, and that they are produced by most 
cell types [64-66]. Their content can be highly varied and can change their make up with subtle 
variations induced in the parent cell of origin. EV recipient cells can be influenced in a wide 
variety of ways by such EVs depending on cell of origin and context of their release and uptake. 
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EV-mediated signaling can occur via protein signaling pathways [67]. They have also been noted 
to play a variety of functions in diseased states such as cancer, dengue, HIV and Tuberculosis. 
1.3.2 Classification and Biogenesis 
EVs are further classified into 3 subgroups namely (a) Apoptotic bodies (b) Ectosomes 
and (c) Exosomes. Apoptotic bodies are larger in size, ranging from 800-5000 nm, originating 
from the blebbing of the plasma membrane of an apoptotic cell. Ectosomes are smaller (50-3000 
nm), originating directly from the fusion of the endosome with plasma membrane, while 
exosomes are the smallest (50-150 nm), arising from invagination of late endosome and being 
released via exocytosis [68, 69]. The biogenesis of EVs depend on a multitude of factors. Initial 
research has shown that formation of exosomes is mediated by endosomal sorting complexes 
required for transport machinery [ESCRT] proteins. This has 4 components ESCRT 0, ESCRT 1, 
ESCRT 2 and ESCRT 3. ESCRT 1 and 2 exert control over the production of membrane buds, 
while ESCRT 3 plays a major role in removing the attachments to endosomal complex and aids 
in generation of intraluminal vesicles (ILV) [70, 71]. There are also ESCRT independent 
exosome production, via cholesterol/lipid raft and tetraspanin involved pathways [72]. EVs have 
high cholesterol/ lipid content on their surface, more than that contained on the inner side of the 
parent cells from which they are derived. Other common molecules observed on the surface of 
exosomes are CD63, CD81, CD9, MHC molecules, and cell-adhesion molecules [73]. Although, 
recent data has shown the origin of exosomes from endocytic compartments to sometimes lack 
these markers, and therefore has led to more refined definitions to the term “exosomes” [74, 75]. 
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Figure 4. Biogenesis of Extracellular vesicles 
(Sangiliyandi Gurunathan et al. cells, 2019)  
Late endosomes arising from the golgi invaginate to form Multi-vesicular bodies, which may/may not fuse with the 
plasma membrane to be released into the extracellular plasma as exosomes [76]. 
 
1.3.3 Uptake and influence in immunological function 
Despite a lot of research on the intercellular transfer and uptake of EVs, there has been no 
conclusive element determined to be responsible for cell uptake. Previous research has varied 
due to many factors including the type of donor and recipient cells being studied, the state of 
these cells, and the heterogeneity of the EVs themselves based on size, origin and surface 
markers expression. Early studies involving murine DC indicated heavy dependence on CD81 
for uptake into DC [77]. Furthermore, the same group also displayed multiple methods of intake 
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including micropinocytosis for small EVs, phagocytosis and fusion/hemifusion of membranes 
[78, 79]. The uptake of EVs can be highly dependent (specific) on the interaction with receptors 
on the surface of recipient cell or non-specific via phagocytosis. Multiple roles of EVs have been 
noted, regarding their ability to modulate various immune functions. B-cell derived EVs having 
enhanced surface expression of MHC II and co-stimulatory molecules, have been demonstrated 
with the ability to directly activate T cells [80]. EVs also carry lipids, proteins, as well as RNA 
(mRNA, miRNA, tRNA), all of which can influence various functions of the recipient cells such 
as cell signaling and blocking of mRNA translation via miRNA delivery to target cells [81]. EVs 
derived from LPS-activated DC loaded with antigen were shown to enhance CD4+ T-cell 
proliferation specific to the antigen of interest, showing a novel role of antigen loaded exosomes 
in priming and polarization of type-1 immune responses, both in-vitro and in-vivo [82]. Further, 
a similar interaction was shown to be enhanced when EVs were internalized by iDC [83]. 
Recently, DC-derived EVs were shown to activate memory CD4+ T cells, but the type and 
extent of response obtained depended on size of EVs [84]. In other reports, Antigen-pulsed DC 
exosomes were as efficient as APC in inducing antibody responses in B-cells and CTL responses 
in-vivo [85, 86], although the type of response was dependent on DC-subtype.  However, these 
studies lacked proof of direct interaction of DC-derived exosomes with these immune cells, thus 
it can be speculated that the effect may have involved the bystander activation of resident DC.  
Nevertheless, these studies suggest that DC-based EVs can influence the response of B cells and 
T-cells in an APC-independent manner.  
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Figure 5. Structure and content of exosomes 
(Sangiliyandi Gurunathan et al., cells, 2019) 
Exosomes contain various molecules which are parent cell specific, obtained from either the surface (Integrins 
binding domains, tetraspanins) or from the cytosol including proteins and mRNA. Bio-molecules such as miRNA 
can be packed which are exosome specific but not found in the parent cell [76]. 
1.3.4 Role in cancer/cancer therapy 
EVs are major role players in the setting of cancer. Since EVs are similar in protein 
composition as their parent cell, tumor specific EVs have increased levels of tumor antigen on 
their MHC. Exosomes from cancer environments are being investigated in their role as 
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functional biomarkers to predict prognosis, via surface markers and miRNA expression levels 
[87, 88]. Initially, this was thought to play a role in enhancing anti-tumor response. For example, 
as shown in-vivo, tumor-derived EVs from various patients were transferred in-vitro to DC, thus 
enhancing the differentiation and proliferation of antigen specific CD8+ T-cells efficiently and 
increasing IFN- levels [89]. Soon, it was seen that DC-derived EV pulsed with tumor antigens 
were more potent in inducing CD8 T-cell responses, thus shifting research focus to this area [90]. 
In 2012, a report published by Stephen et al., displayed the ability of DC-derived exosomes 
attached to dynabeads to kill tumor cells via TNF-related pathways and increase NK-cell anti-
tumor activity [91]. Anti-tumor responses were further enhanced in EVs displaying CD40L 
obtained from modified tumor cells, inducing increased CD80 and CD86 in DC, along with 
superior IFN- and IL-2 expression from splenocytes [92]. Despite the anti-tumor effects of 
tumor-derived EVs, it was noted that these EVs also had immune suppression activity and/or 
aided the spread of cancer in other EV-dependent means. The pro-tumor effect of EVs has been 
demonstrated in Melanoma based vesicles, carrying FAS-L on their surface, which displayed its 
ability in-vitro to induce apoptosis in Fas sensible T-cells [93]. Between 2008 and 2011, in 
independent studies, it was reported that cancer-based EVs enhanced angiogenesis and promoted 
proliferation of endothelial cells via mRNA and other tissue factors packaged in EVs [94, 95]. 
Further studies revealed the presence of factors on cancer-derived EVs, which activate 
plasminogen and exacerbate tumor metastasis [96]. All evidence suggests a potential role of EVs 
in the setting of cancer, thus warranting further studies. 
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1.3.5 Role in infectious diseases 
One of the earliest evidences of EV’s role in infection was observed with both BCG and 
M. Tuberculosis infected macrophages, shedding vesicles with various lipid moieties on their 
surface [97]. In the context of dendritic cells, these cells are the primary source for detection of 
infection. Intense research on effect of DC-infected EVs has been explored in several diseases 
such as Hepatitis C virus (HCV), dengue and HIV. All though not directly infecting DC, HCV-
infected cells were shown by dreux et al., to have proviral effects by transferring HCV RNA to 
pDC via exosomes, implicated to reduce IFN- production during failed cell-cell contact [98]. 
Infection of DC with various dengue strains revealed differential expression of miRNAs in EVs 
between high and low virulent strains and associated differences in signaling pathways such as 
WNT, PI3K/AKT and MAPK [99]. Infection of iDC with HIV-1 particles revealed the 
association of EVs with HIV, in its role to trans-infect CD4+ T cells. Next this was shown to be 
enhanced with mature DC (mDC), revealing a dose dependent uptake of EVs competing with 
HIV suggesting the role of a common mechanism of entry into the cells, dependent on lipid raft-
like moieties. HIV infection of mDC is considered a factor associated with increased trans-
infection while parallel studies indicated a considerable interaction between CD81 and HIV for 
redistribution to DC-T cell contact zones [100, 101]. In 2001, Juan Martin-serrano et al., have 
shown the high dependence of HIV on TSG101 for its egress from infected cell [102], which is 
considered a prominent marker of EVs [74]. 
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1.3.6 Overarching goal of the project 
Based on the background and scientific premise presented, I hypothesize that intercellular 
communication delivered by DC to other cells, including CD8+ T cells, is enhanced as a normal 
immunologic process during infection. Moreover, I hypothesize that polarized DC1, such as the 
described clinically relevant DC1, are superior in this communication process as compared to 
PGE2-matured DC. This belief is due to not only because of the unique capacity of DC1 to 
rapidly form TNT networks, but also for their potential to release EVs in response to CD40L. For 
this thesis, the overarching goals were to 1) Test the ability of differentially polarized DC 
subtypes to transfer cellular content to CD8+ T cells via EV delivery and 2) Characterize the 
phenotype of DC-derived extracellular vesicles and their biologic impact on naïve and memory 
CD8+ antigen specific T cells.  
In addressing these specific aims, it could increase the knowledge of basic immunologic 
functions associated with DC- T-cell communication, which could aid in developing novel 
therapeutic strategies to enhance cytolytic T-cell function in the setting of chronic disease. 
Furthermore, information gained may be helpful in explaining how pathogens, such as HIV-1, 
may utilize or ‘hijack’ this intercellular communication process to facilitate or enhance the 
spread of infection. 
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2.0 Specific Aims 
2.1 Aim 1: Determine the Role of CD40L in DC Capacity to Transfer Content to CD8+ T 
Cells 
This aim focuses on developing a model to aid in visualizing the transfer of content from 
DC to CD8+ T cells and to determine its association with DC polarization status. We 
hypothesize DC1 will enhance transfer to CD8+ T cells induced by their capacity to form TNTs, 
DC2 will fail to amplify this transfer. We will test this hypothesis via the following sub-aims: 
1. Characterize differentially polarized mature DC by analyzing morphology, surface 
marker expression, and their IL12-p70 producing ability following CD40L 
stimulation 
2. Generate GFP-expressing human dendritic cells as a model for intercellular transfer 
3. Determine impact of polarization status on capacity to transfer  
4. Determine the role of TNTs vs extracellular vesicles (EVs) in intercellular transfer 
2.2 Aim 2: Assess the Phenotypic and Immunomodulatory Characteristics of EVs Derived 
from Differentially Polarized DC 
For this aim, we study EVs derived from differentially matured monocyte derived DCs, 
and we assess the impact of CD40L on the production and character of DC derived EVs. We also 
determine the biologic impact that these EVs have on the activation and survival of CD8+ T 
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cells. We hypothesize that EVs derived from CD40L treated DC have immunomodulatory 
properties that will impact the priming and survival of effector CD8+ T cells. This aim will be 
explored through the following Sub-Aims: 
1. Measure quantity and size of EVs produced 
2. Determine EV expression of immunomodulatory surface proteins for different DC 
treatment conditions 
3. Characterize protein content of the DC derived EVs 
4. Describe the biologic impact of DC derived EVs on induction of  primary and 
memory T cell responses 
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3.0 Materials and Methods 
3.1 Isolation of Primary Cells from Blood 
PBMC were obtained from buffy coat or whole blood products from healthy donors 
obtained from the Central Blood Bank of Pittsburgh. For the HIV related studies, blood was 
obtained from men who are participants in the Multicenter AIDS cohort study (MACS), 
Pittsburgh clinical site [103]. The blood samples were isolated by density gradient separation 
method (Corning Cat# 25–072-CV). These were further separated into monocytes and peripheral 
blood lymphocytes (PBLs), using immunomagnetic negative selection method (EasySep: 
STEMCELL Technologies Inc., Vancouver, BC, Canada) 
3.2 Generation of Human DC from Monocytes 
To generate iDC, monocytes isolated from PBMCs via CD14 magnetic bead positive 
selection (Miltenyi) were cultured for 5 days in IMDM (Gibco, Life Technologies, Grand Island, 
NY) containing 10%FBS, or AIM-V (Gibco, Life Technologies, Grand Island, NY) in the 
presence of GM-CSF and IL-4 (both 1000 IU/ml; R&D Systems, Minneapolis, MN). On day 5, 
iDC are exposed to a cocktail of maturation factors for 48 h. For generation of DC1 (DC1), the 
maturation factors consist of TNF- (50 ng/mL), IL-1 (25 ng/mL), Ifn- (3000 units/mL), Ifn- 
(1000 units/mL) and polyisosinic: polycytidilic acid (Poly I:C) (20 ug/mL) [48]. DC2 were 
generated using a modified cocktail, consisting of IL-6 (1000 units/mL), PGE2 (10-6 mol/L), IL-
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1 and TNF-. DC-GFP were generated by infecting iDC at day 4, with an adenoviral-GFP 
vector [104] (a gift from Dr. Walter Storkus, University of Pittsburgh), at MOI of 25 for 24 
hours, followed by the addition of the relevant maturation cocktail used. 
3.3 Activation of Mature DC with CD40L 
Differentially matured DC were stimulated for 24 hours with rhCD40L (0.5 μg/ml; 
MegaCD40L, Enzo Life Sciences). Supernatants were collected for IL-12p70 measurements and 
EV isolation and characterization. 
3.4 Extracellular Vesicle Isolation 
Supernatant was collected by centrifuging at 2000g for 5 mins from the wells containing 
mature DC stimulated after 48 h stimulation rhCD40L (0.5 ug/mL). Supernatant were further run 
through qEV (35-350 nm) columns to obtain purified extracellular vesicles bodies [105].  
3.5 Characterization of Extracellular Vesicles 
Isolated EVs were viewed and characterized by Nanoparticle Track Analysis (NTA) as 
previously described [106]. In short, approximately 0.5mL of sample was loaded into sample 
chamber and 3 videos of 60 seconds were recorded. Using Stokes-Einstein equation, 
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hydrodynamic scattering and diffusion coefficient were obtained and results are displayed as 
particle size distribution and concentration by analyses via Nanosight software.  
3.6 Flowcytometric Analysis 
Cell surface and intracellular staining of CD8+ and CD4+ T cells was carried out as 
previously described [107]. The stains used are as follows: Mouse Anti-human CD3-BV711 (BD 
Biosciences), CD4- Percyp-Cy 5.5 (BD Biosciences), CD8- Pe Cy7 (Biolegend), CD27- BV421 
(BD Biosciences), CD45RA- BV605 (BD Biosciences), CCR7- FITC (ebioscience), PD1- PE 
cy7 (BD Biosciences), CD107- FITC (BD Biosciences), INF-γ- Alex 700 (BD Biosciences), 
CD107- FITC (BD Biosciences), IL2- APC (BD), Mip-1, TNF-- PE (BD Biosciences). 
During experiment and prior to analysis of T-cell responses, stimulation of cells was performed 
with anti CD3/CD28 dynabeads (Gibco, Life Technologies), to mimic antigen cognate 
interaction with DC. Data acquisition was performed using the BD Biosciences LSR Fortessa 
Cell Analyzer, and data was analyzed using the Flow Jo software, version 10.6.1 
3.7 SDS-Page Analysis 
DC-derived EV content was characterized by SDS-PAGE. Briefly, extracellular vesicles 
were lysed with 80-100 uL of lysis/RIPA buffer at and at 4°C for 15 seconds. After centrifuging 
at 14,000 × g for 5 minutes, supernatant was further concentrated and centrifuged at 14,000 × g 
for 5 minutes and supernatant was mixed with 5/1 SDS-running buffer and proteins were 
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separated on 4% SDS-PAGE pre-cast gels. Total protein content was detected with Coomassie 
blue staining. 
3.8 DC T-Cell Coculture 
Differentially matured DC were co-cultured with CD4+/CD8+ T cells or both together at 
a ratio of 1:7 in the presence of SEB (1μg/ml). These cultures were grown together for 5-7 days 
prior to testing with flowcytometry/ ELISPOT. The co-culture was maintained with the addition 
of IL2/IL-7. CD8+ T cells were also challenged with extracellular vesicles at 1:20 ratio for 10-12 
days prior to flowcytometric testing, to help functionally characterize effect of extracellular 
vesicles on CD8+ T cells. 
3.9 IL12-P70/IFN- ELISA 
Supernatant was collected after 24 h stimulation of DC with rhCD40L by centrifuging at 
2000× g for 5 minutes and tested for IL-12p70 and IFN- expression via an IL-12p70 ELISA to 
functionally characterize the DC. 
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3.10 IFN-Gamma ELISpot 
ELISpot assay was implemented to determine IFN- production in PBMCs of HIV+ 
donors treated with differentially polarized dendritic cell-derived extracellular vesicles (EV) pre 
and post CD40L treatment. The assay was performed as previously described in [108] by 
stimulating PBMCs with CEF-peptide (10 ug/mL) and Gag 9mer, TLNAWVKVV (5 mg/mL). 
PBMCs were treated with EVs in ratio 1:20. The assay had a positive control of PBMC 
stimulated with anti-CD3/28 dynabeads and negative controls of PBMCs with no peptide 
stimulation.  
3.11 Recombinant Adenovector 
Adenovirus vector was generated using Cre-Lox recombination based on previously 
described methods [104]. Briefly, the EGFP cDNA was attached to a cytomegalovirus early 
promoter, while simultaneously E1-E3 substituted by cotransduction of EGFP-N1 into packaging 
cell line, CRE8 to be further propagated and purified by density gradient centrifugation. All 
adenoviral vector preparations were handled by Walter storkus’s group and provided to our lab 
as a gift. 
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3.12 Microscopy 
Imaging studies were performed using various imaging techniques. GFP-multivesicular 
bodies localization in CD8+ T cells were conducted via image stream analysis using Amnis flow 
cytometer and analyzed using the IDEAS software. Morphological images of differentially 
matured DC were obtained using Leica bright field microscope. 
3.13 In-Well Western Blot 
Samples are fixed and incubated for 15-20 mins. Post incubation, they were spun for 30 
mins at 4oC at 13,200 rpm., and 0.1% Triton X and 3% BSA were added and the samples were 
gently resuspended and incubated for 1 hr at room temperature. This was followed by a 30 mins 
13,200 rpm centrifugation at 4oC. Supernatants were carefully discarded and blocking buffer was 
added with appropriate secondary antibody-based serum. Unconjugated primary antibody, either 
CD81, PD-L1 or CD86 (all purchased from Santa Cruz Biotechnology) was added and incubated 
overnight at 4C. The next day, samples were spun for 30 mins at 4oC at 13,200 RPM, and pellet 
resuspended in Triton X. The secondary antibody in (1:500) dilution was added and incubated at 
room temperate for 1 hr, spun at 20,000 g and analyzed using LICOR Odyssey Imager. 
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3.14 Trans-Well Assay 
GFP. DC1/DC2 (3x105) were plated in the upper chamber of a 24 well trans-well 
system in 400uL (0.4µm PTFE membrane collagen coated, Costar) along with T-cells (+/- DC) 
in the bottom chamber in a total volume of 1ml IMDM+ 10% FBS (Gibco, Life Technologies, 
Grand Island, NY). Where mentioned, the cultures also contained SEB (1ng/ml) and CD40L (0.5 
μg/ml; MegaCD40L, Enzo Life Sciences). GFP.DC and T-cells were incubated at a ratio of 1:3 
as previously described [84]. The cells at the bottom were harvested 48 hrs post incubation and 
were analyzed for GFP+ content in CD8+ T cells via flowcytometry.  
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4.0 Results 
4.1 Aim 1: To Determine Role of CD40L in DC Capacity to Transfer Content to CD8+ T-
Cells 
4.1.1 Phenotypic characterization of differentially polarized DC 
Differentially polarized DC were generated using previously described methods, with a 
cocktail of cytokines involving either poly(I:C), TNF-α, IL-1β, IFN-α, and IFN-γ for 
DC1(DC1) [48], or IL-1β, TNF-α, IL-6 and PGE2 for DC2 [109]. DC were analyzed for 
prominent surface protein markers by flow cytometry. The gating strategy is depicted in figure 
6A. The alpha DC1 were characterized by their high CD86, moderate CD83 expression and low 















































Figure 6. Mature DC have high expression of co-stimulatory molecules 
(A) Representative gating strategy applied for data analysis of day 6 DC-culture, depicting the DC gating (Left 
panel) and single cell DC (Right panel) (B) Surface markers expression analysis of OX-40L, CD86 and CD83 on 
Alpha DC1 compared to control DC1 unstained. (B) Surface markers expression analysis of OX-40L, CD86 and 
CD83 on DC1 compared to control DC2 unstained. 
 
 
4.1.2 Morphologic characterization of differentially polarized DC 
Differentially polarized DC were also characterized based on morphological changes in 
response to cytokines involved in maturation and their ensuing response to CD4+ T-helper signal 
CD40L assessed by bright field microscopy. On day 6 of culture, DC1 were semi-adherent and 
formed elongated clusters at certain sites of adherence (Figure 7A), while DC2 were rounded and 
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formed less number of clusters (Figure 7B). Furthermore, on stimulating with CD40L, as 
previously shown, DC1 displayed high levels of extensive tunneling nanotube formation (figure 
7C), in comparison to DC2 (figure 7D). 
 
Figure 7. CD4 T-helper signal CD40L induces reticulation via tunneling nanotubes that increases surface 
area 
(A) and (B) show respective morphology of DC1 and DC2 prior to CD40L stimulation. (C) Shows the unique 
ability of DC1 to form tunneling nanotubes (TNTs) in response to CD40L (D) Shows the less efficient ability of 
DC2 to form TNTs in response to CD40L. The TNTs are denoted by green arrows. 
 
4.1.3 Functional characterization of differentially polarized DC 
DC were tested for the ability to produce IL12-p70 in response to CD40L. As expected, 
DC1 produced higher levels of IL12p70 than DC2 post CD40L exposure (Figure 8A). This was 
in correlation with previously developed microarray data, which on further analysis revealed an 
increase in IL12 mRNA in DC1 in response to CD40L (figure 8B), but no relative change in 



















Figure 8. IL12-p70 production of DC1 and DC2 
(A) ELISA shows the higher production of IL12-p70 by alpha DC1+CD40L compared to DC2+CD40L, while both 
have diminished IL12 producing capabilities prior to CD40L exposure. (B) Heatmap from microarray data, showing 
the increased levels of IL12 mRNA after CD40L stimulation in DC1 from 2 different donors (p<0.005). 
 
 
4.1.4 Generation of GFP expressing differentially polarized dendritic cells as a model to 
track intercellular transfer 
We developed a model to track the transfer of cellular content from DC to other cells, 
using GFP content as marker to determine transfer. We did this by engineering DC to express 
GFP, by transducing DC with a replication incompetent GFP-tagged adenoviral vector and 
adding different maturation factors for 2 days. The DC were inspected for GFP expression via 
flow cytometry. Initial analysis revealed that both cell types were transduced with GFP, albeit 
DC1 had lower GFP transduction efficiency than DC2 (Figure 9A, 9B). This led us to 
hypothesize that the IFN-α used in the maturation cocktail for DC1 might have interfered with 
adenoviral transduction due to its anti-viral properties. Hence, we adjusted our protocol by 
transducing the iDC on day 4, exposing them to the adenoviral vector for 24h, and then 
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subsequently added maturation cocktail on day 5 for a 48 h exposure. This indeed increased the 
transduction efficiency,  resulting in a much higher level of GFP expression in the DC1 (termed 
αDC1.GFP; Figure 9C).  
 
 
Figure 9. GFP expression in DC1 and DC2 is comparable when transfected in immature DC stage 
(A) and (B) show the respective low GFP+ DC1 and high GFP+ DC2 when transfected after adding maturation 
cocktail. (C) Shows the high GFP+ DC1 when transfected before adding maturation cocktail. 
 
4.1.5 Assessing the capacity of DC to transfer cellular content to T-cells : Role of CD4+ T 
cell ‘help’ 
The αDC1.GFP that were generated as previously mentioned were co-cultured with T-cells in 
the presence of SEB (used as an antigen surrogate) for 4-6 days. Our specific interest was to determine 
role of CD4 ‘help’ in transferring content to CD8+ T cells. The conditions for this experiment were 
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subdivided into culturing αDC1.GFP with purified T cells containing both CD4+ and CD8+ T cell 
population or with only purified CD8+ T cell fraction. This was followed by flow cytometry analysis of 
the T cells to determine if GFP was transferred.  During the flow cytometry analysis, we observed 
enhanced transfer of GFP to CD8+ T cells cultured in the presence of CD4+ T cells in comparison to 
those cultured in the absence of CD4+ T cells. To see if CD40L signaling was playing a role, we used a 
CD40/CD40L blocking antibody in the assay, which reduced GFP+ CD8 T cells from 25.6% to 9%, 
(Figure 10A and 10B). To further investigate this role of CD4 ‘help’, we substituted CD4+ T cells with a 
synthetic recombinant CD40L activating protein. Flow cytometric analysis of these CD40L treated DC 
revealed an enhanced transfer of GFP to CD8+ T cells from 7.54% to 34% , similar to what was seen in 
the cultures containing the CD4+ T cells (25.6%). We hypothesized that the transfer of GFP to take 
place would be at reduced levels in DC2 cultured with CD8+ T cells, due to their inability of DC2 to 
efficiently express TNTs in the presence of CD40L. Interestingly, we observed that DC2 had similar 














Figure 10. CD4+ T cell 'help' increases efficiency of transfer of DC derived GFP to CD8+ T cells 
(A) Flow cytometric analysis plots following 6 days of co-culture of CD8+ T cells and GFP.DC1+SEB (in all 
conditions from 2nd panel to the left through right). The 1st panel from the left is a negative control with non-
GFP.DC1 as negative control. From 2nd panel to the left to right, the respective conditions are only GFP.DC1 to 
establish baseline transfer of GFP (2nd panel from left), in the presence of CD4+ T cells (middle), in the presence of 
CD4+ T cells and CD40L blocking mAb (2nd panel from right) and in the presence of rhCD40L (right most panel). 
(B) Summarized flow cytometry results of % GFP+ CD8 T cells in various conditions. (C) Summarized flow 
cytometry results of % GFP+ CD8 T cells in DC1 and DC2, enhanced by CD40L 
 
 
4.1.6 Determination of mechanism for intercellular transfer of GFP from GFP.DC to CD8+ 
T cells 
Having addressed the proof of principle that DC can transfer contents to CD8+ T cells, 
and that CD40L was playing a role, we wanted to determine if this effect was contact dependent.  
We hypothesized that the CD40L may be promoting the release of EVs from the DC.  To test 
this idea, we used a trans-well assay system to determine if both DC subtypes invoked similar 
response to CD40L in-terms of producing GFP-EVs. As a positive control, GFP.DC2 were co-
cultured with T-cells in the presence of SEB as described in section 1.1.5 (figure 11A right 
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panel). The cells from the bottom well were harvested 48 hours post incubation and were 
analyzed for GFP positive CD8+ T cells via flow cytometry. The data revealed that while 
GFP.DC1 separated by the membrane did not transfer any GFP to CD8+ T cells (0.41%), 
activation of CD8+ T cells via DC-based CD80/86 lead to 29.8% of CD8+ T cells and 27.9% of 
CD8+ T cells to have GFP from GFP.DC1 (figure 11A middle panel) and GFP.DC2 respectively 
(Data not shown). Together, these collective findings (flow cytometry of DC1 and DC2) support 
our identification of a novel “helper” function of CD40L for facilitating transfer DC cellular cargo 




Figure 11. Contact independent intercellular transfer from DC to CD8+ T cells: Requirement for T cell 
activation 
(A) Experimental layout of trans-well assay. From left to right, the first well consists of GFP.DC1stimulated with 
CD40L in the upper chamber and T-cells with SEB(Ag) in the bottom well and; second well’s lower chamber 
consists of T-cells co-cultured with non.GFP.DC1+SEB(Ag) and GFP.DC1+SEB(Ag)+CD40L in the upper 
chamber; third well is an acting positive control co-culture of GFP.DC and T-cells with CD40L and SEB(Ag) (B) 
Data from flow cytometric analysis summarized in the form of bar graphs showing %GFP+ CD8+ T-cells. 
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Since our experiments suggested that transfer was occurring in a non-contact dependent 
manner, we set out to investigate the potential role of DC derived EVs in our model. To do this, 
we first attempted to generate and isolate GFP.EVs derived from the GFP-DC subtypes we 
engineered through adenoviral transfection as mentioned in section 1.1.4. Using resin-based 
exclusion columns to avoid apoptotic contaminants, we were able to obtain purified small 
extracellular EV (sEV) and medium extracellular EV (mEV) having a size range of 35-350 nm 
(Figure 12A). These EVs were added to cultures of anti-CD3/CD28 bead activated CD8+ T cells 
and imaged to gain better insights about the mechanism of transfer. Preliminary imaging and 
analysis for proof of DC-derived GFP.EVs was determined using AMNIS, image stream 
technology. This revealed an interaction between GFP.EVs and CD8+ T cells (Figure 12B). 
Furthermore, it could be seen that the number of EVs taken up per-cell varied. However due to 
time constraints, we were unable to further analyze and determine the spatial specificities of 








Figure 12. GFP+ extracellular vesicles derived from DC captured by CD8+ T-cells 
(A) Graphic image displaying the process of EV isolation using a resin based size exclusion chromatography system 
isolating EV in 30-300 nm size range. (B) GFP+ EV localization on CD8+ T cells imaged via image-stream flow 
cytometry (Raw data only). 
 
4.2 Aim 2: Assess the Phenotypic and Immunomodulatory Characteristics Of EVs Derived 
From Differentially Polarized DC  
4.2.1 Characterize EVs by size and surface markers 
EVs from differentially polarized DC were isolated and purified from culture supernatant 
at 48h time point post CD40L exposure to avoid the risk of contamination of EVs with apoptotic 
bodies. This was to confirm the existence of EVs by testing for predominant surface markers. 
The EVs showed high levels of tetraspanin (CD81) in the absence of CD40L, while in the case of 
DC1 post CD40L treatment showed tremendous decrease, while the levels remained the same in 
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DC2 with or without CD40L (Figure 13A). These EVs also expressed high levels of CD86, a 
prominent surface marker previously observed on DC-derived EVs [78], with no apparent 
change in either DC condition post CD40L exposure (Figure 13B).  
 
 
Figure 13. Immunodetection in DC1 and DC2 derived vesicles 
(A) In-well western blot image of Immunofluorescent stain for extracelluar vesicle surface marker CD81 (left 
panel). Alpha DC1+CD40L show reduced expression of CD81, but not DC2 (right panel). (B) DC-derived EVs 




The size of EVs was verified by nanoparticle tracking analysis (NTA), which analyzes 
Brownian motion of the particles from video recordings, while simultaneously keeping track of 
individual particle’s scattered light. This revealed a significant decrease in size of DC1 based 
EVs post CD40L (Figure 14B) while significant changes were not observed with DC2 (Data not 


















































of DC-derived EVs ranged from 110 nm to 250 nm. Thus DC-derived EVs were not similar in 
size (+/-) CD40L treatment, while they displayed DC-surface markers at similar levels.  
 
 
Figure 14. Characterization of Extracellular vesicle size distribution 
Alpha DC1-derived EVs were analyzed via nanoparticle tracking analysis (NTA) for relative size distribution with 
representative graph for DC1.EV (left panel) and DC1+CD40L.EV (middle panel). The summarized graph of mean 
size from 3 different experiments (n=3) with error bars (right panel). 
 
4.2.2 Characterize impact of CD40L on internal protein content of EVs  
Having determined the effect of CD40L on surface markers associated with EVs, we 
wanted to see if there was differential packaging of proteins in different DC types, including 
DC1 and DC2 post CD40L stimulation. Following maturation, the DC1 were treated with 
CD40L for 2 days. The EVs from the supernatant were lysed and subsequently analyzed by SDS-
PAGE for total protein expression. The Coomassie blue stain revealed DC1-derived EVs to have 
3 distinct protein bands between 35 and 55 kDa and 2 bands between 15 and 25kDa. In CD40L 
treated DC1-derived EVs, a singular band much stronger in expression was observed between 35 
and 55kDa. Additionally, there was secondary band between 55kDa and 70kDa, which is not 
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observed in control EVs. This confirms that CD40L affects differential packaging of proteins in 
DC1-derived EVs (figure 15).  
 
 
Figure 15. Changes in total-protein of DC1.EV induced by CD40L 
Equal concentrations of internal protein from lysed EVs were separated by SDS-PAGE and stained with Coomassie 
blue for total protein.  2nd lane from the left represents  alpha  DC1.EV.  3rd lane from the left represents alpha 
DC1+CD40L.EV. 1st and last lane are ladders. 
 
Next, we wanted to explore the effect of CD40L on DC2-derived EVs protein. 
Interestingly, the protein expression pattern was comparable in EVs derived from both DC2 and 
CD40L-treated DC2 (figure 16).  This is consistent with the fact that DC2 are less responsive to 
CD40L signaling with regards to morphological changes and IL12p70 production. Since this 
does not account for changes in other materials, which can be transferred such as mRNA and 




Figure 16. Changes in total-protein of DC2.EV induced by CD40L 
Equal concentrations of internal protein from lysed EVs were separated by SDS-PAGE and stained with Coomassie 
blue for total protein. 3rd lane from the left represents DC2.EV. 5th lane from the left represents DC2+CD40L.EV. 1st 




4.2.3 Biologic impact of CD40L treated DC-derived EVs on primary T-cell cultures 
To study the biologic changes induced by EVs, naïve CD8 T cells were activated with 
anti-CD3/CD28 dynabeads and treated with DC-derived EVs for 10-12 days. Images of cultures 
were taken on day 5 post treatment, which showed changes in morphology of the T cell cultures 
in CD40L treated DC-derived EVs compared to control. EV treated cultures showed enhanced 












Figure 17. Activated naïve CD8+ T-cells treated with DC-derived EVs 
All cultures contained naïve CD8+ T cells stimulated with antiCD3/28 bead (A) Shows the control antiCD3/28 
bead-stimulated naïve T-cells (non EV-treated) (B) Shows decrease in T cell expansion (small circumference) in 
cultures treated with EV derived from CD40L-treated DC2 (C) EVs derived from CD40L-treated DC1 induces 
higher amount of proliferation of naïve T cells than other conditions. (All images were captured at 20X by standard 
bright field microscopy). 
 
On day 12 post treatment, the T-cells were stained for markers of effector activity 
including IL2, CD107a, IFN- and Mip-1 to analyze the effect on CD8+ T cells. In the analysis, 
we gated for lymphocytes, single cell discrimination, and live cells (figure 18A). Furthermore, 
during analysis Boolean gating was performed on cells for expression of cytokine combinations 
to obtain data on relative polyfunctionality [107]. Preliminary results indicated a significant 
change (decrease) in the population of cells producing 0 and 1 cytokine T cell cultures treated 
with EVs derived from the CD40L-stimulated DC1 compared to control untreated T cells 
(Ranging between 5-10%), and a significant increase in polyfunctionality especially in % of cells 
producing 2 and 3 cytokines (%) (figure 18B,C), which is an indicative trait of CD8 T cells 
having superior overall effector function [110, 111]. However, there was no significant change 
observed between cultures exposed to the EVs derived from CD40L stimulated DC2 and control 
conditions in-terms of increase in polyfunctionality. Hence CD40L induced DC-derived EVs 
treatment appeared to have the capacity to influence the priming and functional properties CD8+ 
T cells, and this immunomodulatory property is influenced by the mode of DC maturation. 
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However, these findings are limited by the number of donors tested and should be further 
explored with other healthy donors before concrete conclusions can be made.  
 
Figure 18. DC1+CD40L-derived EVs displayed enhanced polyfunctionality of naive CD8 T-cells 
(A)  The gating strategy used for data analysis of day  14  DC. EV treated activated naïve CD8+ T-cells, which 
represents lymphocytes (left panel), CD4/CD8 stain (middle panel) and Boolean gating of % +CD8 T-cells for each 
cytokine.  (B) Summarized pie  charts displaying overall % of CD8+ T cells producing different numbers of 
cytokines.  (C) Bar graph displaying %CD8+ T cells producing different combinationsof  cytokines, CD107-a, 
Interferon-gamma, IL-2 and Mip-1beta. 
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4.2.4 Assessment of CD40L treated DC-derived EVs impact on the long-term function of 
memory CD8+ T cells following challenge with HIV-1/CEF antigen expressing targets 
Having observed a positive effect of these EVs on priming of naïve CD8+ T-cells, we 
wanted to study the effect of these EVs on the activation of virus specific memory CTLs CEF 
and HIV- specific. Using specimens from HIV+ participants from the MACS cohort, we cultured 
their PBMC in the presence of either CEF (CMV, Epstein-Barr and Influenza) peptide or HIV 
Gag peptide and cultured them for 10-12 days in the presence or absence of EVs derived from 
CD40L-treated DC. These cell cultures were supplemented with IL2 and IL7 on day 5 and tested 
for functional response in IFN-gamma ELISPOT on day 10-12. Overall, compared to the control 
(Untreated), DC-derived EV treated PBMCs had lower percentage of CEF specific IFN- 
producing CTLs. This effect was exacerbated in CD40L treated DC-derived EV, which held true 
for the EVs derived from both DC1 and DC2 subtypes (figure 19A). The same effect was 
observed in HIV-1 antigen specific IFN- producing CTLs (figure 19B). These results directly 
contradict the effect seen in naïve T-cells. We hypothesized a change in impact based on the 
characteristics of memory vs naïve T-cell and while also taking into consideration previous data 
published by Garcia-Bates et al, showing the increased PD-L1 expression on CD40L treated DC, 
and a context dependent and opposing impacts of DC-derived PD-L1 on the function of naïve vs 






Figure 19. Memory T-cells were negatively regulated by DC derived EVs 
(A) IFN-gamma assay results from HIV+ donors of PBMCs stimulated with CMV-EBV-Flu antigen in the presence 
of various DC-derived EVs. (B) IFN-gamma assay results from HIV+ donors of PBMCs stimulated with HIV-
specific antigen in the presence of various DC-derived EVs (Representative of 2 experiments/ n=2). 
 
PD-L1 is an inhibitory ligand found predominantly in cancer patients and long-term HIV 
progressors [112]. To initially confirm this, we analyzed for PD-L1 expression in both DC-types 
via flow cytometry (figure 20A), which corroborated with previously seen results. Thus, we 
performed in-well western blotting on DC-derived EVs for PD-L1 and subsequently found slight 
increase in PD-L1 expression in CD40L treated DC1.EV, while no apparent changes were 




Figure 20. PD-L1 expression is profound on mature DC 
(A) Surface marker analysis of PD-L1 on DC1 and DC2 (B) In-well western blot immunofluorescent staining of DC-










The ability of DC to modulate immunologic functions of various adaptive immune cells 
is a basic area of immunology with enormous potential yet to be completely utilized. Recently, 
data from the Storkus lab hinted at the ability of DC overexpressing T-bet to transfer content to 
T-cells in T-bet knocked out murine model [53]. Potentially related to these findings, a study by 
Zaccard et al., highlighted a pivotal role of CD40L on DC1, facilitating the formation of TNTs in 
a process referred to as ‘reticulation’, which aids in inter-DC communication and intercellular 
transfer of content between DC [42]. While there is emerging evidence of increased CTL killing 
potential induced by DC1 is related to their superior responsiveness to CD40L on CD4+ T helper 
cells, however it is unclear if DC reticulation and intercellular transfer of content to CTL directly 
is playing a role in enhancing CTL priming. Therefore, in this project, we sought to explore the 
potential for DC and CD8+ T cells to directly exchange of information, with emphasis on T-
helper signal CD40L in enhancing such intercellular communication and DC1-mediated CTL 
responses. 
In my first aim, we hypothesized that DC1, because of their unique capacity to reticulate 
in response to CD40L, would have better potential to communicate with CD8+ T cells as 
compared to DC2. As a proof of principle, we aimed to visualize the transfer via Adv-GFP 
transduction of DC. Upon initial examination, we found low baseline levels of GFP transfer was 
occurring between DC1 and CD8+ T cells and was greatly enhanced in the presence of CD4+ T 
cells or recombinant CD40L, further corroborated by CD40L blockade (figure 10A). 
Surprisingly, DC2 displayed similar levels of GFP handover to CD8+ T cells (figure 10C), 
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revealing a novel function of CD40L in promoting DC transfer of cellular cargo directly to 
CD8+ T cells, with similar efficiency in both mature DC types tested.   
While the exact nuances of the CD40-CD40L signaling pathway responsible for this 
transfer is yet to be fully explained, we sought to confirm the messenger capability of EVs via 
trans-well assays and image stream flow cytometry. Preliminary results of DC-generated EVs 
showed the accumulation of GFP-EVs on CD8+ T cells (figure 12B). While performing trans-
well assays, we observed GFP transfer from DC to T-cells only when T-cells were activated. 
While unclear, this role of activation on T-cells may be due to increased expression of certain 
surface markers/receptors that may play a role facilitating uptake of EVs via phagocytosis or 
endocytosis. This does not undermine the potential role of TNTs in this phenomenon, since the 
efficiency of the transfer in the trans-well assays was lower than when the cells co-culture with 
direct contact permitted. Our results also indicate the role of CD40L on DC generation and 
transfer of EVs, potentially with a specialized immunomodulatory function. 
 For my 2nd aim, we sought out to characterize and explore the functional role of CD40L 
induced DC-derived EVs. We investigated their ability to modulate the induction of primary and 
memory CTL responses. We observed that CD40L-treated DC1 generated EVs that were smaller 
in size than those from CD40L-treated DC2. Subsequently, quantification of the prominent 
exosome related surface marker CD81, revealed diminished levels in the same sub-type 
following CD40L stimulation, while the expression of the DC-associated costimulatory molecule 
CD86 helped distinguish them as indeed originating from the parent DC [78]. Although the 
implications of this are for the most part still unknown, inhibition of CD81 has been shown to 
decrease uptake of EVs into other types of target cells [77]. The decrease in size might correlate 
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with an exosome like feature, which have more potent immunomodulatory capacities than 
medium or large sized EVs [74, 79]. 
Although there were phenotypic differences noted, this itself does not indicate differences 
in content or function. Previously published data from our lab, as also shown in Aim1, has 
revealed the noticeable reaction of DC1 to CD40L characterized by the high level of production 
of IL12-p70 and better CTL inducing capacity [48]. We sought to examine the possibility that 
such CTL responses were partially enhanced as a result of EV delivery, and in particular 
influenced by modifications in internal content of EVs specifically derived from CD40L-
stimulated DC1. From SDS-PAGE, there were several protein bands observed in EVs collected 
from untreated DC1, whereas in EVs derived from CD40L-treated DC1 did not result in these 
bands being expressed. Instead a protein band between 55kDa and 70 kDa was upregulated, 
which could correspond to a higher expression of T-bet or IL12-p70. As expected, the changes in 
DC2-derived EVs were subtle and showed no major differences resulting from CD40L exposure.  
To determine the potential immune impact of these CD40L induced DC-derived EVs, we 
first specifically tested their impact on the primary activation of naïve T-cells.  As a surrogate of 
antigen specific activation by antigen presenting mature DC, we used anti-CD3/CD28 activation 
beads as the primary activator of the naïve T cells. Although the results are preliminary, we 
observed differences in the induction of polyfunctional effector responses when DC derived EVs 
were present during this primary stimulation, with a significant increase noted in the percentage 
of CD8+ T cells producing 2 or 3 cytokines in EVs derived from the CD40L stimulated DC1, 
compared to those derived from DC2-EV. These data are consistent with internal phenotypic and 
content changes noted with the CD40L stimulated DC1, further suggesting a potential role of 
CD40L ‘help’ in influencing the quality of primary CTL immunity.    
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Surprisingly, when we performed similar experiments to induce the activation of memory 
T-cell responses to HIV and CEF peptides (using PBMC collected from HIV infected MACS 
participants), the presence of DC-derived EVs resulted in diminished cytolytic responses, 
suggesting an inhibitory role of DC-derived EVs. Moreover, this highlights that the function of 
the EVs may be context dependent, greatly influenced by the differentiation stage of the T cells 
they target. Based on the findings from a previous report from our group describing a similar 
context dependent effect on T cells resulting from PD-L1 expression on DC, which is enhanced 
upon CD40L stimulation, we hypothesize that the effect could be due to EV expression of PD-L1 
t [40]. Indeed, we did find a high degree of expression of PD-L1 on the DC-derived EVs.  This 
could also imply EV-mediated differential functional impact on different types of T-cells, 
whereby they function to shut down exhausted memory T-cells and to stimulate priming of naïve 
T-cells.  
As mentioned before, these novel findings may be a novel immunologic mechanism and 
may help to explain findings from others regarding the mechanisms by which migratory DC 
mediate cytolytic responses by transferring information to resident DC following their initial 
interaction with CD4+ T helper cells [44]. CD40L dependent transfer from DC to T cells may 
also be a mechanism utilized or hijacked by HIV spread infection to other T cells, which 
theoretically could include CD8+ T cells [113]. While all of these are speculative, to my 
knowledge this is the first study to dwell into the effect of CD40L on DC-derived EVs and their 
potential biologic impact on CD8+ T cells, thus describing a novel helper function of CD40L 
expressing CD4+ T helper cells, and highlighting the fact that there still basic immunological 
mechanisms that have yet to be fully explored. A better understanding of this immunologic 
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phenomenon may lead to the development of effective therapeutic strategies to treat chronic 
diseases such as HIV.   
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6.0 Public Health Significance 
Dendritic cells (DC) are the natural link between the innate and the adaptive immune 
system. Their central role in the immune response has been the reason that DC have been 
evaluated and utilized as a tool for the development of vaccines against chronic diseases 
including cancer and HIV. Despite the success of ART, there still is no cure for chronic HIV 
infection. Developing an immunotherapeutic method design to effectively control HIV, similar 
to those few ‘elite controllers’ who can do this naturally, has been a primary goal in the field of 
HIV cure research. There are a number of major hurdles to address to achieve this immunologic 
‘functional cure’, which include CTL exhaustion/dysfunction, viral evolution and immune 
escape, and HIV latency itself. The strategy of “Kick and Kill” for HIV cure is an area of 
research where DC are actively being explored for their potential in both inducing long-lived 
polyfunctional CTL that can focus attack on highly conserved regions of HIV, as well as driving 
HIV latency reversal [9, 114, 115]. 
Even though DC are amongst the most well studied cells in the immune system, due to 
high degree of tissue-based differences, and their incredibly wide range of functions, many basic 
biologic aspects of how they work and communicate with other immune cells still have yet to be 
fully elucidated. For example, the central dogma in DC biology is that they acquire antigen in the 
peripheral tissue and migrate to draining lymph nodes to induce CTL responses. More recently, it 
has been shown that migratory DC are required for delivery of antigen and instruction to lymph 
node resident DC to induced effective CD8+ T cell responses, and this is done through some 
unknown mechanism [43]. Moreover, their expression of high levels of PD-L1 have been 
suggested to play important, albeit opposing roles, on the induction of primary CTL responses vs 
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the regulation of memory CTL responses, through mechanisms that remain unclear [40].  
Importantly, viruses such as HIV have targeted the functional programming DC as a means to 
escape immune control and to enhance viral dissemination [116, 117]. A clearer picture of their 
basic function is still critically important for the development of improved immunotherapeutics 
and for understanding how pathogens may utilize them or modify their behavior to their 
advantage.   
CD40L has long been known to play a major ‘helper’ role in DC-mediated CTL 
responses.  In recent years, the role of CD40L has been shown to be critical to various and newly 
discovered aspects of DC functions, including inducing DC1 reticulation, or the immunologic 
process by which DC form tunneling nanotube networks that support intercellular 
communication and antigen transfer amongst DC [42]. CD40L has also been shown to mediate 
opposing immunoregulatory effects on T-cells via upregulation and activation of the PD-L1 
signaling pathways [40]. Unpublished data from the Mailliard laboratory has suggested an 
important role for CD40L in CD4+ T cell : DC interactions leading to enhanced DC-mediated 
HIV trans-infection. And finally, inhibition of CD40L signaling of DC has been shown to lessen 
their capacity to drive latency reversal and expression of HIV protein in latently infected CD4+ 
T cells. In all of these cases, the mechanisms involved in the CD40L mediated effect have yet to 
be elucidated.   
DC-derived extracellular vesicles (EVs) have recently been tied to antigen specific CD4+ 
and CD8+ T-cell responses and explored as drug delivery systems and vaccination strategies [91, 
92]. Until now, DC derived EVs have typically been studied following their collection as a result 
of their non-specific release in culture supernatants. Our finding that signaling via the CD4+ T 
helper cell factor CD40L results in the purposeful packaging and release of DC-derived EVs, and 
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that they serve as a vehicle to transfer cellular content to T cells to influence T cell function 
suggest the discovery of a novel DC-mediated helper function of CD40L. The link between 
CD40L-induced DC-derived EVs and T-cells is an unexplored paradigm that may be critical to 
many immunological functions, situation and outcomes, and thus warrants further investigation. 
My thesis research work has significance and potential impact to public health in various 
aspects. The first way has to do with improving our understanding of basic immunology.  
The immune system is critical to every component of health, including but not limited to wound 
healing, fighting off microbial invaders, psychology, and digestion. Understanding how EVs 
derived from such a central player of the immune system are produced and function 
immunologically could be extremely valuable.  One can imagine that such knowledge could then 
lead to the bioengineering of EV-based immunotherapeutic strategies to treat a number of 
health conditions, including HIV infection, cancer, and autoimmune conditions. Moreover, 
understanding how to better isolate them and analyze their phenotypic, content, and functional 
characteristics could lead to the development of EV-based biomarker assays for the purpose 
of identifying, assessing, or monitoring certain human health conditions. And finally, 
understanding the role of CD40L-induced DC-derived EVs and their mechanisms of formation 
and action could lead to a better understanding of how microbes might circumvent, modify, 
or utilize them for their survival advantage. 
57 
Bibliography 
1. Poiesz, B.J., et al., Detection and isolation of type C retrovirus particles from fresh and 
cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U 
S A, 1980. 77(12): p. 7415-9. 
2. Johnson, S.C. and J.G. Gerber, Advances in HIV/AIDS therapy. Adv Intern Med, 2000. 
45: p. 1-40. 
3. Ekong, E., et al., Epidemiologic and viral predictors of antiretroviral drug resistance 
among persons living with HIV in a large treatment program in Nigeria. AIDS Res Ther, 
2020. 17(1): p. 7. 
4. Rebucci, M. and C. Michiels, Molecular aspects of cancer cell resistance to 
chemotherapy. Biochem Pharmacol, 2013. 85(9): p. 1219-26. 
5. Adams, G.P. and L.M. Weiner, Monoclonal antibody therapy of cancer. Nat Biotechnol, 
2005. 23(9): p. 1147-57. 
6. Almasbak, H., T. Aarvak, and M.C. Vemuri, CAR T Cell Therapy: A Game Changer in 
Cancer Treatment. J Immunol Res, 2016. 2016: p. 5474602. 
7. Archin, N.M. and D.M. Margolis, Emerging strategies to deplete the HIV reservoir. Curr 
Opin Infect Dis, 2014. 27(1): p. 29-35. 
8. Jones, R.B., et al., Histone deacetylase inhibitors impair the elimination of HIV-infected 
cells by cytotoxic T-lymphocytes. PLoS Pathog, 2014. 10(8): p. e1004287. 
9. Kristoff, J., et al., Type 1-programmed dendritic cells drive antigen-specific latency 
reversal and immune elimination of persistent HIV-1. EBioMedicine, 2019. 43: p. 295-
306. 
10. Palucka, A.K., et al., Immunotherapy via dendritic cells. Adv Exp Med Biol, 2005. 560: 
p. 105-14. 
11. Banchereau, J. and A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer. 
Nat Rev Immunol, 2005. 5(4): p. 296-306. 
12. Joffre, O.P., et al., Cross-presentation by dendritic cells. Nat Rev Immunol, 2012. 12(8): 
p. 557-69. 
13. Lu, W., et al., Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med, 
2004. 10(12): p. 1359-65. 
14. Porgador, A. and E. Gilboa, Bone marrow-generated dendritic cells pulsed with a class I-
restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med, 1995. 
182(1): p. 255-60. 
15. Steinman, R.M. and J. Banchereau, Taking dendritic cells into medicine. Nature, 2007. 
449(7161): p. 419-426. 
16. Mellman, I. and R.M. Steinman, Dendritic cells: specialized and regulated antigen 
processing machines. Cell, 2001. 106(3): p. 255-8. 
17. Purcell, A.W. and T. Elliott, Molecular machinations of the MHC-I peptide loading 
complex. Curr Opin Immunol, 2008. 20(1): p. 75-81. 
18. Neefjes, J., et al., Towards a systems understanding of MHC class I and MHC class II 
antigen presentation. Nat Rev Immunol, 2011. 11(12): p. 823-36. 
58 
19. Wolf, P.R. and H.L. Ploegh, How MHC class II molecules acquire peptide cargo: 
biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol, 
1995. 11: p. 267-306. 
20. Sercarz, E.E. and E. Maverakis, Mhc-guided processing: binding of large antigen 
fragments. Nat Rev Immunol, 2003. 3(8): p. 621-9. 
21. Inaba, K., et al., The formation of immunogenic major histocompatibility complex class 
II-peptide ligands in lysosomal compartments of dendritic cells is regulated by 
inflammatory stimuli. J Exp Med, 2000. 191(6): p. 927-36. 
22. Horig, H., et al., Strategies for cancer therapy using carcinoembryonic antigen vaccines. 
Expert Rev Mol Med, 2000. 2(3): p. 1-24. 
23. Guermonprez, P., et al., Antigen presentation and T cell stimulation by dendritic cells. 
Annu Rev Immunol, 2002. 20: p. 621-67. 
24. Allison, J.P., CD28-B7 interactions in T-cell activation. Curr Opin Immunol, 1994. 6(3): 
p. 414-9. 
25. Corthay, A., A three-cell model for activation of naive T helper cells. Scand J Immunol, 
2006. 64(2): p. 93-6. 
26. Sallusto, F. and A. Lanzavecchia, The instructive role of dendritic cells on T-cell 
responses. Arthritis Res, 2002. 4 Suppl 3: p. S127-32. 
27. Mora, J.R., et al., Selective imprinting of gut-homing T cells by Peyer's patch dendritic 
cells. Nature, 2003. 424(6944): p. 88-93. 
28. Mora, J.R., et al., Reciprocal and dynamic control of CD8 T cell homing by dendritic 
cells from skin- and gut-associated lymphoid tissues. J Exp Med, 2005. 201(2): p. 303-16. 
29. Jutel, M. and C.A. Akdis, T-cell Subset Regulation in Atopy. Current Allergy and Asthma 
Reports, 2011. 11(2): p. 139-145. 
30. Ridge, J.P., F. Di Rosa, and P. Matzinger, A conditioned dendritic cell can be a temporal 
bridge between a CD4+ T-helper and a T-killer cell. Nature, 1998. 393(6684): p. 474-8. 
31. Schoenberger, S.P., et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-
CD40L interactions. Nature, 1998. 393(6684): p. 480-3. 
32. Bennett, S.R.M., et al., Help for cytotoxic-T-cell responses is mediated by CD40 
signalling. Nature, 1998. 393(6684): p. 478-480. 
33. Koch, F., et al., High level IL-12 production by murine dendritic cells: upregulation via 
MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med, 
1996. 184(2): p. 741-6. 
34. Feau, S., et al., The CD4+ T-cell help signal is transmitted from APC to CD8+ T-cells 
via CD27–CD70 interactions. Nature Communications, 2012. 3(1): p. 948. 
35. Kalinski, P., et al., Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-
12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood, 2001. 
97(11): p. 3466-9. 
36. Seder, R.A., et al., Interleukin 12 acts directly on CD4+ T cells to enhance priming for 
interferon gamma production and diminishes interleukin 4 inhibition of such priming. 
Proc Natl Acad Sci U S A, 1993. 90(21): p. 10188-92. 
37. Kalinski, P., et al., IL-12-deficient dendritic cells, generated in the presence of 
prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper 
cells. J Immunol, 1997. 159(1): p. 28-35. 
38. Castle, B.E., et al., Regulation of expression of the ligand for CD40 on T helper 
lymphocytes. The Journal of Immunology, 1993. 151(4): p. 1777-1788. 
59 
39. Howland, K.C., et al., The roles of CD28 and CD40 ligand in T cell activation and 
tolerance. J Immunol, 2000. 164(9): p. 4465-70. 
40. Garcia-Bates, T.M., et al., Contrasting Roles of the PD-1 Signaling Pathway in Dendritic 
Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. 
Journal of Virology, 2019. 93(5): p. e02035-18. 
41. Sheppard, K.A., et al., PD-1 inhibits T-cell receptor induced phosphorylation of the 
ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett, 2004. 
574(1-3): p. 37-41. 
42. Zaccard, C.R., et al., CD40L induces functional tunneling nanotube networks exclusively 
in dendritic cells programmed by mediators of type 1 immunity. J Immunol, 2015. 194(3): 
p. 1047-56. 
43. Allan, R.S., et al., Migratory dendritic cells transfer antigen to a lymph node-resident 
dendritic cell population for efficient CTL priming. Immunity, 2006. 25(1): p. 153-62. 
44. Lee, H.K., et al., Differential roles of migratory and resident DCs in T cell priming after 
mucosal or skin HSV-1 infection. J Exp Med, 2009. 206(2): p. 359-70. 
45. Palucka, K. and J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines. 
Immunity, 2013. 39(1): p. 38-48. 
46. Kaliński, P., et al., Final Maturation of Dendritic Cells Is Associated with Impaired 
Responsiveness to IFN-γ and to Bacterial IL-12 Inducers: Decreased Ability of Mature 
Dendritic Cells to Produce IL-12 During the Interaction with Th Cells. The Journal of 
Immunology, 1999. 162(6): p. 3231-3236. 
47. Jonuleit, H., et al., Pro-inflammatory cytokines and prostaglandins induce maturation of 
potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J 
Immunol, 1997. 27(12): p. 3135-42. 
48. Mailliard, R.B., et al., α-Type-1 Polarized Dendritic Cells. A Novel Immunization Tool 
with Optimized CTL-inducing Activity, 2004. 64(17): p. 5934-5937. 
49. Park, M.H., et al., Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic 
Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against 
Breast Cancer. Cancer Res Treat, 2011. 43(1): p. 56-66. 
50. Wesa, A., et al., Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 
family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J 
Immunother, 2007. 30(1): p. 75-82. 
51. Lee, J.J., et al., Type 1-polarized dendritic cells loaded with autologous tumor are a 
potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol, 2008. 84(1): p. 
319-25. 
52. Okada, H., et al., Induction of CD8+ T-cell responses against novel glioma-associated 
antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized 
dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and 
carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol, 2011. 
29(3): p. 330-6. 
53. Qu, Y., et al., Intralesional delivery of dendritic cells engineered to express T-bet 
promotes protective type 1 immunity and the normalization of the tumor 
microenvironment. J Immunol, 2010. 185(5): p. 2895-902. 
54. Connolly, N.C., B.A. Colleton, and C.R. Rinaldo, Treating HIV-1 infection with dendritic 
cells. Current opinion in molecular therapeutics, 2007. 9(4): p. 353-363. 
60 
55. Lu, W., et al., Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nature 
Medicine, 2004. 10(12): p. 1359-1365. 
56. Zhao, X.-Q., et al., Induction of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) 
CD8<sup>+</sup> and CD4<sup>+</sup> T-Cell Reactivity by Dendritic Cells 
Loaded with HIV-1 X4-Infected Apoptotic Cells. Journal of Virology, 2002. 76(6): p. 
3007-3014. 
57. Macatangay, B.J. and C.R. Rinaldo, Regulatory T cells in HIV immunotherapy. HIV 
Ther, 2010. 4(6): p. 639-647. 
58. Garcia, F., et al., A dendritic cell-based vaccine elicits T cell responses associated with 
control of HIV-1 replication. Sci Transl Med, 2013. 5(166): p. 166ra2. 
59. Andrés, C., et al., HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral 
Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell 
Responses. Journal of Virology, 2015. 89(18): p. 9189-9199. 
60. Surenaud, M., et al., Anti-HIV potency of T-cell responses elicited by dendritic cell 
therapeutic vaccination. PLoS Pathog, 2019. 15(9): p. e1008011. 
61. van der Sluis, R.M., et al., Dendritic cell-induced activation of latent HIV-1 provirus in 
actively proliferating primary T lymphocytes. PLoS Pathog, 2013. 9(3): p. e1003259. 
62. Macatangay, B.J., et al., Therapeutic Vaccination With Dendritic Cells Loaded With 
Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis, 2016. 213(9): p. 1400-9. 
63. Kristoff, J., C.R. Rinaldo, and R.B. Mailliard, Role of Dendritic Cells in Exposing Latent 
HIV-1 for the Kill. Viruses, 2019. 12(1). 
64. Harding, C., J. Heuser, and P. Stahl, Endocytosis and intracellular processing of 
transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a 
pathway for receptor shedding. Eur J Cell Biol, 1984. 35(2): p. 256-63. 
65. Chargaff, E. and R. West, The biological significance of the thromboplastic protein of 
blood. J Biol Chem, 1946. 166(1): p. 189-97. 
66. Trams, E.G., et al., Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. 
Biochim Biophys Acta, 1981. 645(1): p. 63-70. 
67. Yanez-Mo, M., et al., Biological properties of extracellular vesicles and their 
physiological functions. J Extracell Vesicles, 2015. 4: p. 27066. 
68. Gould, S.J. and G. Raposo, As we wait: coping with an imperfect nomenclature for 
extracellular vesicles. J Extracell Vesicles, 2013. 2. 
69. Yamamoto, S., et al., Significance of Extracellular Vesicles: Pathobiological Roles in 
Disease. Cell Struct Funct, 2016. 41(2): p. 137-143. 
70. Eitan, E., et al., Impact of lysosome status on extracellular vesicle content and release. 
Ageing Res Rev, 2016. 32: p. 65-74. 
71. Hurley, J.H., ESCRT complexes and the biogenesis of multivesicular bodies. Curr Opin 
Cell Biol, 2008. 20(1): p. 4-11. 
72. Pfrieger, F.W. and N. Vitale, Cholesterol and the journey of extracellular vesicles. J 
Lipid Res, 2018. 59(12): p. 2255-2261. 
73. Yoshioka, Y., et al., Comparative marker analysis of extracellular vesicles in different 
human cancer types. J Extracell Vesicles, 2013. 2. 
74. Kowal, J., et al., Proteomic comparison defines novel markers to characterize 
heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A, 
2016. 113(8): p. E968-77. 
61 
75. Witwer, K.W. and C. Théry, Extracellular vesicles or exosomes? On primacy, precision, 
and popularity influencing a choice of nomenclature. Journal of Extracellular Vesicles, 
2019. 8(1): p. 1648167. 
76. Gurunathan, S., et al., Review of the Isolation, Characterization, Biological Function, 
and Multifarious Therapeutic Approaches of Exosomes. Cells, 2019. 8(4). 
77. Morelli, A.E., et al., Endocytosis, intracellular sorting, and processing of exosomes by 
dendritic cells. Blood, 2004. 104(10): p. 3257-66. 
78. Montecalvo, A., et al., Mechanism of transfer of functional microRNAs between mouse 
dendritic cells via exosomes. Blood, 2012. 119(3): p. 756-66. 
79. Mathieu, M., et al., Specificities of secretion and uptake of exosomes and other 
extracellular vesicles for cell-to-cell communication. Nature Cell Biology, 2019. 21(1): p. 
9-17. 
80. Robbins, P.D. and A.E. Morelli, Regulation of immune responses by extracellular 
vesicles. Nat Rev Immunol, 2014. 14(3): p. 195-208. 
81. Pegtel, D.M., et al., Functional delivery of viral miRNAs via exosomes. Proc Natl Acad 
Sci U S A, 2010. 107(14): p. 6328-33. 
82. Qazi, K.R., et al., Antigen-loaded exosomes alone induce Th1-type memory through a B-
cell-dependent mechanism. Blood, 2009. 113(12): p. 2673-83. 
83. Vincent-Schneider, H., et al., Exosomes bearing HLA-DR1 molecules need dendritic cells 
to efficiently stimulate specific T cells. Int Immunol, 2002. 14(7): p. 713-22. 
84. Tkach, M., et al., Qualitative differences in T-cell activation by dendritic cell-derived 
extracellular vesicle subtypes. Embo j, 2017. 36(20): p. 3012-3028. 
85. Del Cacho, E., et al., Induction of protective immunity against Eimeria tenella infection 
using antigen-loaded dendritic cells (DC) and DC-derived exosomes. Vaccine, 2011. 
29(21): p. 3818-25. 
86. Colino, J. and C.M. Snapper, Exosomes from bone marrow dendritic cells pulsed with 
diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive 
recipients in the absence of free antigen. J Immunol, 2006. 177(6): p. 3757-62. 
87. Welker, M.W., et al., Soluble serum CD81 is elevated in patients with chronic hepatitis C 
and correlates with alanine aminotransferase serum activity. PLoS One, 2012. 7(2): p. 
e30796. 
88. Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer 
detection. Proc Natl Acad Sci U S A, 2008. 105(30): p. 10513-8. 
89. Andre, F., et al., Malignant effusions and immunogenic tumour-derived exosomes. 
Lancet, 2002. 360(9329): p. 295-305. 
90. Hao, S., et al., Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses 
and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol, 2006. 
3(3): p. 205-11. 
91. Munich, S., et al., Dendritic cell exosomes directly kill tumor cells and activate natural 
killer cells via TNF superfamily ligands. Oncoimmunology, 2012. 1(7): p. 1074-1083. 
92. Wang, J., et al., More efficient induction of antitumor T cell immunity by exosomes from 
CD40L gene-modified lung tumor cells. Mol Med Rep, 2014. 9(1): p. 125-31. 
93. Martinez-Lorenzo, M.J., et al., The human melanoma cell line MelJuSo secretes bioactive 
FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor 
counterattack. Exp Cell Res, 2004. 295(2): p. 315-29. 
62 
94. Skog, J., et al., Glioblastoma microvesicles transport RNA and proteins that promote 
tumour growth and provide diagnostic biomarkers. Nat Cell Biol, 2008. 10(12): p. 1470-
6. 
95. Hong, B.S., et al., Colorectal cancer cell-derived microvesicles are enriched in cell 
cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics, 
2009. 10: p. 556. 
96. McCready, J., et al., Secretion of extracellular hsp90alpha via exosomes increases cancer 
cell motility: a role for plasminogen activation. BMC Cancer, 2010. 10: p. 294. 
97. Beatty, W.L., et al., Trafficking and release of mycobacterial lipids from infected 
macrophages. Traffic, 2000. 1(3): p. 235-47. 
98. Dreux, M., et al., Short-range exosomal transfer of viral RNA from infected cells to 
plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe, 2012. 12(4): p. 
558-70. 
99. Martins, S.T., et al., Characterization of Dendritic Cell-Derived Extracellular Vesicles 
During Dengue Virus Infection. Front Microbiol, 2018. 9: p. 1792. 
100. Dong, C., et al., Characterization of human immunodeficiency virus type 1 replication in 
immature and mature dendritic cells reveals dissociable cis- and trans-infection. J Virol, 
2007. 81(20): p. 11352-62. 
101. Garcia, E., et al., HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a 
pathway of tetraspanin sorting to the immunological synapse. Traffic, 2005. 6(6): p. 488-
501. 
102. Martin-Serrano, J., T. Zang, and P.D. Bieniasz, HIV-1 and Ebola virus encode small 
peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat 
Med, 2001. 7(12): p. 1313-9. 
103. Detels, R., et al., The multicenter AIDS Cohort Study, 1983 to …. Public Health, 2012. 
126(3): p. 196-198. 
104. Ranieri, E., et al., Dendritic cells transduced with an adenovirus vector encoding 
Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol, 
1999. 73(12): p. 10416-25. 
105. Boing, A.N., et al., Single-step isolation of extracellular vesicles by size-exclusion 
chromatography. J Extracell Vesicles, 2014. 3. 
106. Soo, C.Y., et al., Nanoparticle tracking analysis monitors microvesicle and exosome 
secretion from immune cells. Immunology, 2012. 136(2): p. 192-7. 
107. Mailliard, R.B., et al., Selective Induction of CTL Helper Rather Than Killer Activity by 
Natural Epitope Variants Promotes Dendritic Cell–Mediated HIV-1 Dissemination. The 
Journal of Immunology, 2013. 191(5): p. 2570-2580. 
108. Colleton, B.A., et al., Primary human immunodeficiency virus type 1-specific CD8+ T-
cell responses induced by myeloid dendritic cells. J Virol, 2009. 83(12): p. 6288-99. 
109. Bender, A., et al., Improved methods for the generation of dendritic cells from 
nonproliferating progenitors in human blood. J Immunol Methods, 1996. 196(2): p. 121-
35. 
110. Bihl, F., et al., Cellular immune responses and disease control in acute AIDS-associated 
Kaposi's sarcoma. AIDS, 2009. 23(14): p. 1918-22. 
111. Betts, M.R., et al., HIV nonprogressors preferentially maintain highly functional HIV-
specific CD8+ T cells. Blood, 2006. 107(12): p. 4781-9. 
63 
112. Day, C.L., et al., PD-1 expression on HIV-specific T cells is associated with T-cell 
exhaustion and disease progression. Nature, 2006. 443(7109): p. 350-4. 
113. Tiran, B., et al., HIV infection of CD8 cells. Lancet, 1996. 348(9040): p. 1527-8. 
114. Sanyal, A., et al., Novel assay reveals a large, inducible, replication-competent HIV-1 
reservoir in resting CD4(+) T cells. Nat Med, 2017. 23(7): p. 885-889. 
115. Smith, K.N., et al., Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 
during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells. mBio, 2016. 
7(3). 
116. Mailliard, R.B., et al., Selective induction of CTL helper rather than killer activity by 
natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination. J 
Immunol, 2013. 191(5): p. 2570-80. 
117. Rappocciolo, G., N. Sluis-Cremer, and C.R. Rinaldo, Efficient HIV-1 Trans Infection of 
CD4+ T Cells Occurs in the Presence of Antiretroviral Therapy. Open Forum Infectious 
Diseases, 2019. 6(7). 
 
